Hamlet BioPharma AB
Develops novel treatments for cancer and infections, with candidates in Phase II trials.
HAMLET | SPGR
Overview
Corporate Details
- ISIN(s):
- SE0015661145 (+2 more)
- LEI:
- 549300HJV2LJY4CDBR64
- Country:
- Sweden
- Address:
- Klinikgatan 32, 222 42 LUND
- Website:
- https://hamletbiopharma.com/
- Sector:
- Manufacturing
Description
Hamlet BioPharma AB is a pharmaceutical company developing novel treatments for cancer and infections. Its lead oncology candidate, Alpha1H, is designed to selectively target and kill tumor cells while sparing healthy tissue. Alpha1H has completed Phase II clinical trials for bladder cancer, demonstrating significant tumor reduction and the activation of an anti-tumor immune response. The company is also advancing immunotherapy as an alternative to antibiotics. A Phase II trial using the IL-1 inhibitor anakinra for recurrent acute cystitis (urinary tract infections) showed efficacy comparable to standard antibiotic treatment. Another Phase II study demonstrated that anakinra significantly reduced symptoms and improved quality of life for patients with Bladder Pain Syndrome.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Hamlet BioPharma AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Hamlet BioPharma AB
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Hamlet BioPharma AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
